Reuters logo
BRIEF-Ironwood Pharmaceuticals announces approval of LINZESS (linaclotide) in Japan for the treatment of adults with IBS-C
December 19, 2016 / 11:35 AM / 10 months ago

BRIEF-Ironwood Pharmaceuticals announces approval of LINZESS (linaclotide) in Japan for the treatment of adults with IBS-C

Dec 19 (Reuters) - Ironwood Pharmaceuticals Inc

* Ironwood Pharmaceuticals announces approval of LINZESS (linaclotide) in Japan for the treatment of adults with IBS-C

* Ironwood Pharmaceuticals says Astellas Pharma secured marketing approval from Japanese Ministry of Health, Labor and Welfare for LINZESS in Japan

* Ironwood Pharmaceuticals says phase III trial of linaclotide in patients with chronic constipation ongoing in Japan, with top-line data expected in 2017

* Anticipates that astellas will launch drug in first half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below